Recce Pharmaceuticals (ASX:RCE) announced that the Brazilian National Institute of Industrial Property has granted a Family 4 patent for its proprietary synthetic anti-infectives.
The milestone provides the company with exclusive rights in the Brazilian market until 2041, further solidifying its position as a leader in the development of a new class of treatments designed to combat increasingly resistant pathogens.
The newly granted patent specifically covers the preparation and application of Recce's flagship compounds, RECCE 327 (R327) and RECCE 529 (R529).
The claims are broad, encompassing the treatment of a wide array of bacterial and viral infections.
The patent validates the use of these anti-infectives against critical medical challenges such as Acute Bacterial Skin and Skin Structure Infections, diabetic foot infections, and burn wounds.
Furthermore, the protection extends to respiratory and systemic threats, including influenza, SARS-CoV-2, and hospital-acquired pneumonia.
The granted claims support administration via oral, inhalation, and transdermal routes, as well as various injection methods, including intravenous and intramuscular.
The Brazilian approval marks Recce's seventh Family 4 patent, joining an international stable that includes Australia, China, Japan, and the United States.
At the time of reporting, Recce Pharmaceuticals' share price was $0.51.